By Lisa Thompson NYSE:MHH READ THE FULL MHH RESEARCH REPORT After seven quarters of declining year-over-year revenues, Mastech (NYSE:MHH) reported revenue growth of 8.5% in Q3 2024. Gross margin was again at an all-time high, and income is growing faster than revenues. As a result, we are raising our Q4 2024 and 2025 EPS estimates … Read more
By Thomas Kerr, CFA NYSE:TWI READ THE FULL TWI RESEARCH REPORT 3rd Quarter 2024 Financial and Operating Results Titan International (NYSE:TWI) reported 3rd quarter 2024 financial results which continued to reflect a difficult macro environment in most of its end markets as the OEM destocking story continues to evolve. Net sales for the 3rd quarter … Read more
By Michael Kim NASDAQ:CPSS READ THE FULL CPSS RESEARCH REPORT After the market closed on 10/31/24, Consumer Portfolio Services (NASDAQ:CPSS) reported 3Q24 earnings results. For the quarter, CPSS reported net income of $4.8 million, or $0.20 per share – a penny shy of our $0.21 EPS estimate. Relative to our model, despite more favorable revenues, … Read more
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its 510(k) premarket filing submission for the semi-active mBôs TKA System. … Read more
NASDAQ:GRCE | NASDAQ:ACST Since the recording of this interview, the company has changed its name to Grace Therapeutics and is now trading under NASDAQ:GRCE. John Viglotti: Hello, and welcome to Virtual Investor Conferences. My name’s John Viglotti, and on behalf of OTC Markets and our co-host, Zacks Small Cap Research, we’re very pleased you joined … Read more
